143 related articles for article (PubMed ID: 16361251)
1. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.
Zheng Z; Cai C; Omwancha J; Chen SY; Baslan T; Shemshedini L
J Biol Chem; 2006 Feb; 281(7):4002-12. PubMed ID: 16361251
[TBL] [Abstract][Full Text] [Related]
2. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L
Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317
[TBL] [Abstract][Full Text] [Related]
3. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.
Bawa-Khalfe T; Cheng J; Wang Z; Yeh ET
J Biol Chem; 2007 Dec; 282(52):37341-9. PubMed ID: 17932034
[TBL] [Abstract][Full Text] [Related]
4. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.
Kaikkonen S; Jääskeläinen T; Karvonen U; Rytinki MM; Makkonen H; Gioeli D; Paschal BM; Palvimo JJ
Mol Endocrinol; 2009 Mar; 23(3):292-307. PubMed ID: 19116244
[TBL] [Abstract][Full Text] [Related]
5. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription.
Nishida T; Yasuda H
J Biol Chem; 2002 Nov; 277(44):41311-7. PubMed ID: 12177000
[TBL] [Abstract][Full Text] [Related]
6. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.
Sutinen P; Rahkama V; Rytinki M; Palvimo JJ
Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374
[TBL] [Abstract][Full Text] [Related]
7. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus.
Rytinki M; Kaikkonen S; Sutinen P; Paakinaho V; Rahkama V; Palvimo JJ
Mol Cell Biol; 2012 Oct; 32(20):4195-205. PubMed ID: 22890844
[TBL] [Abstract][Full Text] [Related]
8. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
9. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.
Cai C; Hsieh CL; Omwancha J; Zheng Z; Chen SY; Baert JL; Shemshedini L
Mol Endocrinol; 2007 Aug; 21(8):1835-46. PubMed ID: 17505060
[TBL] [Abstract][Full Text] [Related]
10. SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR SUMOylation.
Wu R; Cui Y; Yuan X; Yuan H; Wang Y; He J; Zhao J; Peng S
Toxicol Lett; 2014 Sep; 229(2):405-13. PubMed ID: 25014244
[TBL] [Abstract][Full Text] [Related]
11. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP.
Sato N; Sadar MD; Bruchovsky N; Saatcioglu F; Rennie PS; Sato S; Lange PH; Gleave ME
J Biol Chem; 1997 Jul; 272(28):17485-94. PubMed ID: 9211894
[TBL] [Abstract][Full Text] [Related]
12. The single-macro domain protein LRP16 is an essential cofactor of androgen receptor.
Yang J; Zhao YL; Wu ZQ; Si YL; Meng YG; Fu XB; Mu YM; Han WD
Endocr Relat Cancer; 2009 Mar; 16(1):139-53. PubMed ID: 19022849
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
17. Negative modulation of androgen receptor transcriptional activity by Daxx.
Lin DY; Fang HI; Ma AH; Huang YS; Pu YS; Jenster G; Kung HJ; Shih HM
Mol Cell Biol; 2004 Dec; 24(24):10529-41. PubMed ID: 15572661
[TBL] [Abstract][Full Text] [Related]
18. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
Cao X; Qin J; Xie Y; Khan O; Dowd F; Scofield M; Lin MF; Tu Y
Oncogene; 2006 Jun; 25(26):3719-34. PubMed ID: 16449965
[TBL] [Abstract][Full Text] [Related]
19. SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.
Holmstrom SR; Chupreta S; So AY; Iñiguez-Lluhí JA
Mol Endocrinol; 2008 Sep; 22(9):2061-75. PubMed ID: 18562626
[TBL] [Abstract][Full Text] [Related]
20. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.
Mukherjee S; Thomas M; Dadgar N; Lieberman AP; Iñiguez-Lluhí JA
J Biol Chem; 2009 Aug; 284(32):21296-306. PubMed ID: 19497852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
